| Third Rock Gets $616M to Grow New Crop of Biotech Startups | Ben Fidler | 10/31/16 | Boston |
| With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher | Ben Fidler | 08/31/15 | New York |
| Orphan Drug From Scioderm Aims to Treat Rare Skin Disease | Frank Vinluan | 10/07/14 | Raleigh Durham |
| Editor’s Picks: Xconomy Boston’s Top 20 Stories of Q1 2013 | Gregory T. Huang | 04/01/13 | Boston |
| Third Rock Stocks Up With $516M New Fund, Looks to Start 16 Cos | Luke Timmerman | 03/25/13 | Boston |
| Biotech VCs Aren’t Lemmings Anymore. They’re Lone Rangers | Luke Timmerman | 03/25/13 | National |
| East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist | Bernadette Tansey | 03/01/13 | Boston |
| Third Rock’s Bet on Lotus Tissue Repair Generates Big Return | Luke Timmerman | 02/27/13 | Boston |
| East Coast Life Sciences Roundup: Bind, Boston Children’s, J&J, More | Catherine Arnst | 01/11/13 | Boston |
| Mid-Priced Biotechnology Companies Bloom As M&A Targets in 2013 | Bernadette Tansey | 01/10/13 | San Francisco |
| Shire Pharmaceuticals Acquires Lotus Tissue Repair for Undisclosed Sum | VentureDeal | 01/09/13 | Boston |
| Shire Buys Third Rock’s Lotus Tissue Repair | Catherine Arnst | 01/08/13 | Boston |
| Sabet and Wilson Out at Twitter, Hirshland Out at Polaris, & More VC Comings and Goings | Gregory T. Huang | 09/22/11 | Boston |
| VC Investments in Boston Companies Soar to 1999 Levels ($1B+); Here Are the Top 10 Deals from the 2nd Quarter | Gregory T. Huang | 07/21/11 | Boston |
| Zynga Files For IPO, Brightcove Inks Boston Lease, Lotus Adds $26M, & More Boston-Area Deals News | Erin Kutz | 07/06/11 | Boston |
| Acetylon Adds $27M, Third Rock Leads Lotus Round, InfraReDx Gets $24M, & More Boston-Area Life Sciences News | Erin Kutz | 07/01/11 | Boston |
| Lotus Pioneers New Treatment for Rare and Disfiguring Disorder, Raises $26 Million From Third Rock | Arlene Weintraub | 06/30/11 | Boston |
| Lotus Tissue Repair Lands $26,000,000 Series A Financing Round | VentureDeal | 06/30/11 | Boston |
